Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 1
2005 2
2006 2
2007 2
2008 5
2009 7
2010 1
2011 5
2012 11
2013 6
2014 7
2015 3
2016 13
2017 9
2018 9
2019 12
2020 14
2021 8
2022 4
2023 9
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. Kimball AB, et al. Among authors: reguiai z. Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. Lancet. 2023. PMID: 36746171 Clinical Trial.
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB. Kimball AB, et al. Among authors: reguiai z. N Engl J Med. 2016 Aug 4;375(5):422-34. doi: 10.1056/NEJMoa1504370. N Engl J Med. 2016. PMID: 27518661 Free article. Clinical Trial.
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, Crépy MN, Stingeni L, Serra-Baldrich E, Baranowski K, Korn S, Kurvits M, Plohberger U, Strange Vest N, Schliemann S; trial investigators. Bissonnette R, et al. Lancet. 2024 Aug 3;404(10451):461-473. doi: 10.1016/S0140-6736(24)01027-4. Epub 2024 Jul 18. Lancet. 2024. PMID: 39033766 Clinical Trial.
Evolution of dupilumab-associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO-ADOC study).
Reguiai Z, Becherel PA, Perrot JL, Boulard C, Fougerousse AC, Begon E, Badaoui A, Poreaux C, Parier J, Liegeon AL, Levavasseur M, Bing AC, Estève E, Maccari F; GEM reso‐Dermatologie and OMCCI Group. Reguiai Z, et al. J Eur Acad Dermatol Venereol. 2024 Nov;38(11):2149-2155. doi: 10.1111/jdv.20233. Epub 2024 Jul 17. J Eur Acad Dermatol Venereol. 2024. PMID: 39015045
Compared Burden of Psoriasis, Atopic Dermatitis, Hidradenitis Suppurativa, and Chronic Urticaria: Baseline Characteristics of the Patients Included in the OMCCI Cohort - A French, Prospective Multicenter Study of Chronic Inflammatory Dermatoses.
Becherel PA, Reguiai Z, Fougerousse AC, Perrot JL, Begon E, Thomas-Beaulieu D, Mery-Bossard L, Pourchot D, Boulard C, Fite C, Beaziz J, Zaraa I, Lons-Danic D, Badaoui A, Parier J, Chaby G, Estève E, Liegeon AL, Patchinsky A, Muller P, Lepelley-Dupont C, Poreaux C, Jacobzone-Lévêque C, Chassain K, Mohty R, Perrussel M, Garcia C, Girard C, Dillies AS, Amy de la Breteque M, Quiles-Tsimaratos N, Denis D, Maccari F. Becherel PA, et al. Among authors: reguiai z. Dermatology. 2024;240(5-6):702-712. doi: 10.1159/000540250. Epub 2024 Jul 17. Dermatology. 2024. PMID: 39019015
Combining Omalizumab with Another Biotherapy.
Fougerousse AC, Becherel PA, Pallure V, Boyé T, Reguiai Z, Gabison G, Barthelemy H, Badaoui A, Mahé E, Livideanu CB; GEM ResoPso. Fougerousse AC, et al. Among authors: reguiai z. Acta Derm Venereol. 2019 Apr 1;99(4):448-449. doi: 10.2340/00015555-3140. Acta Derm Venereol. 2019. PMID: 30723874 Free article. No abstract available.
Association between hidradenitis suppurativa and spondyloarthritis.
Fauconier M, Reguiai Z, Barbe C, Colosio A, Eschard JP, Salmon JH, Direz G. Fauconier M, et al. Among authors: reguiai z. Joint Bone Spine. 2018 Oct;85(5):593-597. doi: 10.1016/j.jbspin.2017.09.005. Epub 2017 Sep 28. Joint Bone Spine. 2018. PMID: 28965938
Impact of Baricitinib on Patients' Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry.
Reguiai Z, Becherel PA, Perrot JL, Fougerousse AC, Begon E, Poreaux C, Boulard C, Chaby G, Fite C, Zaraa I, Lons-Danic D, Liegeon AL, Parier J, Quiles-Tsimaratos N, David L, Maccari F. Reguiai Z, et al. Acta Derm Venereol. 2023 Oct 6;103:adv14153. doi: 10.2340/actadv.v103.14153. Acta Derm Venereol. 2023. PMID: 37800349 Free PMC article.
115 results